Medifast (MED) Tops Q3 EPS by 3c; Mixed Outlook

Medifast (NYSE: MED) reported Q3 EPS of $0.45, $0.03 better than the analyst estimate of $0.42. Revenue for the quarter came in at $65.9 million versus the consensus estimate of $67 million.

Medifast sees Q4 2015 EPS of $0.31-$0.35, versus the consensus of $0.41. Medifast sees Q4 2015 revenue of $60.5-63.5 million, versus the consensus of $63.82 million.

Medifast sees FY2015 EPS of $1.72-$1.76, versus the consensus of $1.67. Medifast sees FY2015 revenue of $272-275 million, versus the consensus of $276.34 million.

"Our top line results, solid gross margin expansion and expense leverage enabled us to generate earnings above our guidance for the third quarter," said Michael C. MacDonald, Medifast Chairman and Chief Executive Officer. "We are pleased with the sequential improvement in our business and our meaningful progress to advance the growth and simplification of Take Shape For Life. Moving forward, our team remains focused on executing our strategic initiatives as we improve the efficiency across our differentiated sales channels to help drive higher revenues and profitability long-term."

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
• Novo Nordisk (NVO) Tops Q3 EPS by 117c; offers outlook
• Varonis Systems (VRNS) Tops Q3 EPS by 6c